Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series
Acta Haematologica · 2024
DOI: 10.1159/000534445 ↗Kurz gefasst
Fallbericht in der Zeitschrift Acta Haematologica, 2024. Verfasst von Shawn P Griffin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California, USA, spgriffi…. Hauptthemen laut MEDLINE: Antifungal Agents, Azoles, Hematopoietic Stem Cell Transplantation, Ritonavir.
Abstract (Originalsprache)
Introduction
Nirmatrelvir/ritonavir (NIM/r) inhibits tacrolimus metabolism resulting in a profound drug-drug interaction that is further complicated by the use of azole antifungals. Case Presentations: We describe three strategies, in 4 patient cases, for the initiation of NIM/r in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients on tacrolimus at the time of diagnosis. Patients 1 and 2 (strategy 1) experienced prolonged, elevated tacrolimus concentrations after an empiric 33% reduction in tacrolimus dose and adjustment of azole antifungal at NIM/r initiation (strategy 1) and with complete discontinuation of tacrolimus and azole antifungal at NIM/r initiation (strategy 2). Patients 3 and 4 (strategy 3) did not experience elevated tacrolimus concentrations on NIM/r treatment with complete discontinuation of tacrolimus and azole antifungal and a 12–24-h delay in NIM/r initiation. Reinitiation of tacrolimus after NIM/r completion resulted in variable tacrolimus concentrations.
Conclusion
NIM/r-tacrolimus is a serious drug-drug interaction which can be mitigated by early discontinuation of tacrolimus and azole antifungals, close monitoring, and reinitiation of tacrolimus and antifungal 48–72 h after completion of therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California, USA, spgriffi@hs.uci.edu.
- Department of Pharmacy, University of California Irvine Health, Orange, California, USA, spgriffi@hs.uci.edu.
- Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California, USA.
- Department of Pharmacy, University of California Irvine Health, Orange, California, USA.
- Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
- Division of Infectious Diseases, Department of Medicine, University of California Irvine Health, Orange, California, USA.
Zitieren
APA
Griffin, S. P., Lee, B., Doh, J., Paradyse, A. R., Jeyakumar, D., Arter, Z., Nam, H., Blodget, E., Smith, J., Valek, A., Vittayawacharin, P., Kongtim, P., & Ciurea, S. O. (2024). Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series. Acta Haematologica. https://doi.org/10.1159/000534445
Vancouver
Griffin SP, Lee B, Doh J, Paradyse AR, Jeyakumar D, Arter Z, et al. Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series. Acta Haematologica. 2024. doi:10.1159/000534445
BibTeX
@article{Griffin2024,
author = {Griffin, Shawn P and Lee, Benjamin and Doh, Jean and Paradyse, Alexander R and Jeyakumar, Deepa and Arter, Zhaohui and Nam, Hannah and Blodget, Emily and Smith, Julie and Valek, Anitram and Vittayawacharin, Pongthep and Kongtim, Piyanuch and Ciurea, Stefan O},
title = {Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000534445}
}
EUVIMED